InVitae Corp (NASDAQ:NVTA) VP Patty Dumond sold 2,497 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $10.00, for a total value of $24,970.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Patty Dumond also recently made the following trade(s):

  • On Monday, October 9th, Patty Dumond sold 1,882 shares of InVitae Corp stock. The shares were sold at an average price of $10.00, for a total value of $18,820.00.

InVitae Corp (NVTA) traded up 0.10% during mid-day trading on Wednesday, hitting $9.95. The company had a trading volume of 233,223 shares. The stock’s market capitalization is $433.26 million. The stock has a 50 day moving average price of $9.36 and a 200-day moving average price of $9.36. InVitae Corp has a 1-year low of $5.76 and a 1-year high of $11.88.

InVitae Corp (NASDAQ:NVTA) last announced its earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The business had revenue of $14.34 million for the quarter, compared to analysts’ expectations of $13.31 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The firm’s quarterly revenue was up 157.0% compared to the same quarter last year. On average, analysts forecast that InVitae Corp will post ($2.35) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Insider Selling: InVitae Corp (NVTA) VP Sells 2,497 Shares of Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/11/insider-selling-invitae-corp-nvta-vp-sells-2497-shares-of-stock.html.

A number of institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in InVitae Corp by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 3,974,227 shares of the medical research company’s stock worth $43,955,000 after purchasing an additional 25,100 shares during the period. Vanguard Group Inc. raised its position in InVitae Corp by 9.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,323,137 shares of the medical research company’s stock worth $12,649,000 after purchasing an additional 116,871 shares during the period. ARK Investment Management LLC raised its position in InVitae Corp by 30.4% in the 2nd quarter. ARK Investment Management LLC now owns 982,170 shares of the medical research company’s stock worth $9,390,000 after purchasing an additional 229,189 shares during the period. State Street Corp raised its position in InVitae Corp by 43.1% in the 2nd quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock worth $5,528,000 after purchasing an additional 174,016 shares during the period. Finally, Northern Trust Corp raised its position in InVitae Corp by 39.0% in the 2nd quarter. Northern Trust Corp now owns 433,113 shares of the medical research company’s stock worth $4,140,000 after purchasing an additional 121,409 shares during the period.

A number of research analysts have recently issued reports on the company. Zacks Investment Research raised InVitae Corp from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research note on Wednesday. BidaskClub raised InVitae Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $15.00 price objective (up from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. InVitae Corp presently has a consensus rating of “Buy” and an average price target of $13.50.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Insider Buying and Selling by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.